Open access · OA
via OpenAlex
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Ping Jin, Jingwen Jiang, Li Zhou, Zhao Huang, Edouard C. Nice, Canhua Huang, Li Fu
Journal of Hematology & Oncology · 2022 · ▲ 250 citations
Abstract
Drug resistance represents a major obstacle in cancer management, and the mechanisms underlying stress adaptation of cancer cells in response to therapy-induced hostile environment are largely unknown. As the central organelle for cellular energy supply, mitochondria can rapidly undergo dynamic changes and integrate cellular signaling pathways to provide bioenergetic and biosynthetic flexibility for cancer cells, which contributes to multiple aspects of tumor characteristics, including drug resistance. Therefore, targeting mitochondria for cancer therapy and overcoming drug resistance has attracted increasing attention for various types of cancer. Multiple mitochondrial adaptation processes, including mitochondrial dynamics, mitochondrial metabolism, and mitochondrial apoptotic regulatory machinery, have been demonstrated to be potential targets. However, recent increasing insights into mitochondria have revealed the complexity of mitochondrial structure and functions, the elusive functions of mitochondria in tumor biology, and the targeting inaccessibility of mitochondria, which have posed challenges for the clinical application of mitochondrial-based cancer therapeutic strategies. Therefore, discovery of both novel mitochondria-targeting agents and innovative mitochondria-targeting approaches is urgently required. Here, we review the most recent literature to summarize the molecular mechanisms underlying mitochondrial stress adaptation and their intricate connection with cancer drug resistance. In addition, an overview of the emerging strategies to target mitochondria for effectively overcoming chemoresistance is highlighted, with an emphasis on drug repositioning and mitochondrial drug delivery approaches, which may accelerate the application of mitochondria-targeting compounds for cancer therapy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s13045-022-01313-4
- Canonical
- link ↗
- Fetched
- 2026-06-06 MST
Cite this
APA
Jin, P., Jiang, J., Zhou, L., Huang, Z., Nice, E.C., Huang, C., & Fu, L. (2022). Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. <em>Journal of Hematology & Oncology</em>. https://doi.org/10.1186/s13045-022-01313-4
Vancouver
Jin P, Jiang J, Zhou L, Huang Z, Nice EC, Huang C, et al. Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. Journal of Hematology & Oncology. 2022. doi:10.1186/s13045-022-01313-4.
BibTeX
@article{ping2022Mitoch,
title = {Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management},
author = {Ping Jin and Jingwen Jiang and Li Zhou and Zhao Huang and Edouard C. Nice and Canhua Huang and Li Fu},
journal = {Journal of Hematology & Oncology},
year = {2022},
doi = {10.1186/s13045-022-01313-4},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
biorxiv 2024
Preprint · CC-BY
Capsaicin acts as a novel NRF2 agonist to suppress ethanol induced gastric mucosa oxidative damage by directly disrupting the KEAP1-NRF2 interaction
Current Neuropharmacology 2023
Preprint · CC-BY
Pharmacological Progress of Mitophagy Regulation
Genes & Development 2010
Open access · OA
Molecular genetics of prostate cancer: new prospects for old challenges
Autophagy 2010
Open access · OA
ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy
Stem Cell Research & Therapy 2025
Open access · CC-BY
The role of the mTOR pathway in breast cancer stem cells (BCSCs): mechanisms and therapeutic potentials
biorxiv 2024
Preprint · CC-BY